Beta Fulltext view is in preview — article structure may vary. Browse all articles
Contents
Nanomedicine & Nanotechnology Open Access Research Article 18 min read

AI Powered Identification of Drug Targets and Pathways for Diagnosis and Treatment Planning: A Review

Sharma A*
* Corresponding author
ISSN: 2574-187X  10.23880/nnoa-16000232  Received: May 16, 2023  Published: May 25, 2023
 — views
 50 references
PDF
Keywords
Artificial Intelligence Drug Targets Diagnosis Treatment
Abstract

AI has become an integral part of drug discovery, particularly in the identification of drug targets and pathways for diagnosis and treatment planning. By using machine learning algorithms to analyze large datasets, AI can identify potential drug targets and predict drug efficacy, potentially streamlining the drug development process and improving patient outcomes. In this article, we have discussed the emerging role of AI in the discovery of drug targets and pathways for diagnosis and treatment planning. We have explored how AI is being used to identify potential drug targets by analyzing large-scale genomic and proteomic data. Additionally, we have discussed how AI can predict drug efficacy by analyzing patient data, leading to more personalized treatment plans and improved patient outcomes. We also highlighted the use of AI in biomarker discovery and some challenges in the implementation of AI in drug discovery, such as the need for large amounts of high-quality data and the interpretability of AI-generated results.

Introduction

Artificial intelligence (AI) is an area that, in its most basic form, combines computer science and substantial datasets to facilitate problem-solving [1]. Additionally, it includes the branches of artificial intelligence known as deep learning and machine learning, which are commonly addressed together. These fields use AI algorithms to build expert systems that make predictions or categorize information based on incoming data. Today, AI is used in the medical field to analyze vast amounts of patient data, identify disease patterns, and assist in the development of personalized treatment options, leading to improved patient outcomes [2].

AI and machine learning are transforming the field of drug discovery by accelerating the identification of drug targets and pathways for the diagnosis and treatment planning of various diseases. With the explosion of big data in healthcare, AI has the potential to revolutionize drug discovery and development by analyzing vast amounts of data from various sources, including genetic information, protein structures, and clinical outcomes [3].

The traditional drug discovery process is long and complex, involving multiple stages of drug development, including target identification, target validation, lead identification, and clinical trials [4]. The process is also expensive, with a high failure rate and low success rate. The use of AI and machine learning in drug discovery can speed up the process and reduce the cost by predicting the efficacy of drugs, identifying new drug targets, and designing new molecules [5]. One of the key applications of AI in drug discovery is the identification of drug targets [6]. AI can analyze large datasets of genetic information, protein structures, and signaling pathways to identify potential drug targets. By analyzing this data, AI algorithms can identify targets that are involved in disease progression, and can be modulated by drugs [7]. This information can be used to develop new therapies for diseases with limited treatment options [8].

Once a potential drug target is identified, AI can be used to validate its role in disease progression [9]. This involves predicting the effect of inhibiting or activating the target on the disease phenotype. AI algorithms can predict the changes in gene expression and protein activity that occur when a drug targets a specific protein [10]. This information can be used to identify the most promising drug candidates for further development. AI can also be used to predict the efficacy of drugs on specific targets by analyzing large datasets of gene expression and clinical outcomes. This involves training algorithms to predict how different drugs will affect the expression of specific genes or proteins [11]. By comparing the predicted effects of different drugs, AI can identify the most effective treatment options for specific diseases.

Biomarker discovery is another area where AI is having a significant impact on drug discovery [12]. Biomarkers are molecular or cellular features that can be used to diagnose diseases, monitor disease progression, and predict treatment response [13, 14]. AI can analyze large datasets of patient data, including genetic and clinical data, to identify biomarkers that can be used for disease diagnosis and patient stratification. This can lead to personalized treatment options and improve patient outcomes.

AI can also assist in treatment planning by analyzing large amounts of patient data, including genetic and clinical data, to predict the most effective treatment options for individual patients [15]. This involves training algorithms to predict how different patients will respond to different drugs based on their genetic makeup and clinical history. By tailoring treatment options to individual patients, AI can improve treatment outcomes and reduce the risk of adverse events [16]. AI-powered identification of drug targets and pathways has the potential to revolutionize the drug discovery process, leading to more effective and personalized treatment options for various diseases and disorders. The use of AI and machine learning in drug discovery can accelerate the identification of drug targets, predict the efficacy of drugs, identify biomarkers for disease diagnosis and monitoring, and improve treatment outcomes by tailoring treatment options to individual patients. With the increasing availability of big data in healthcare, the use of AI in drug discovery is likely to become even more widespread in the future.

AI in Drug Target Identification

In the past, the identification of drug targets was a lengthy and costly process that involved a great deal of trial and error [17]. Researchers would perform experiments to identify the role of different proteins, genes, or other biological factors in disease development and progression. However, the process was often slow and prone to errors and biases.

The use of AI in drug target identification has changed the way researchers approach drug discovery [18]. AI algorithms can analyze vast amounts of biological data, such as genetic information, protein structures, and signalling pathways, to identify potential targets for drugs that can treat various diseases and disorders [19]. This can save time, reduce costs, and lead to more accurate and targeted drug development. AI can help researchers identify patterns and relationships in data that may be missed by human researchers, leading to more accurate and targeted drug development. For example, researchers can use AI to analyze the genetic mutations present in cancer cells and identify the specific proteins that are driving tumour growth [20]. They can then develop drugs that specifically target those proteins, leading to more effective cancer treatments.

One of the key advantages of using AI in drug target identification is that it can help researchers identify novel drug targets that may have been overlooked through traditional research methods. By analyzing vast amounts of data, AI can identify potential drug targets that researchers may not have considered previously [21]. Overall, the use of AI in drug target identification has the potential to revolutionize the drug discovery process. It can lead to the development of more effective treatments for a range of diseases and disorders, and it can do so more quickly and at a lower cost than traditional research methods. As such, AI is rapidly becoming an essential tool in the field of drug discovery.

AI in Predicting Drug Efficacy

“AI in Predicting Drug Efficacy” refers to the use of AI in predicting how well a drug is likely to work in treating a specific disease or condition [22].

Traditionally, drug efficacy has been evaluated using clinical trials, which can be expensive and time-consuming. AI can help predict drug efficacy by analysing large datasets of genetic, molecular, and clinical data to identify potential drug candidates and to determine which patients are most likely to respond positively to a particular treatment [5].

AI algorithms can analyse and integrate data from multiple sources, including electronic health records, genomic data, and clinical trials, to identify patterns and relationships that can inform drug development and treatment decision-making [21, 23]. By leveraging this data, AI can help researchers identify potential drug candidates that may have been missed using traditional research methods and can predict how well a drug is likely to work in different patient populations. One of the key advantages of using AI in predicting drug efficacy is the ability to develop personalized treatment plans that are tailored to individual patients’ unique medical profiles [24, 25]. AI can predict which patients are likely to respond positively to a particular drug, and can also identify potential adverse effects and drug interactions [26].

Overall, the use of AI in predicting drug efficacy has the potential to significantly improve the drug development process and to develop more effective treatments for a range of diseases and conditions. It can help reduce costs, speed up the drug development process, and lead to more targeted and personalized treatment options for patients [27].

AI in Drug Discovery

AI has the potential to revolutionize the drug discovery process by identifying novel drug candidates more quickly and efficiently [11, 12]. By leveraging AI algorithms to analyze and integrate large and complex datasets, researchers can identify promising drug candidates that may have been missed using traditional research methods. Below are some examples that shows how AI is used by different organizations for drug discovery.

One example of AI in drug discovery is the use of deep learning algorithms to identify new drug compounds. Deep learning algorithms can analyze large datasets of chemical and biological data to identify new compounds with potential therapeutic properties [28]. For example, researchers at BenevolentAI used deep learning algorithms to identify a potential new drug candidate for amyotrophic lateral sclerosis (ALS) [29]. The algorithm analyzed over 1 billion chemical compounds and identified a compound that had not previously been associated with ALS but showed promise in preclinical models [12].

Another example is the use of AI to identify drug candidates for rare and neglected diseases [30]. These diseases often receive less attention from pharmaceutical companies due to the small patient populations and limited financial incentives. However, AI can help identify potential drug candidates for these diseases by analyzing data from a range of sources, including scientific literature and clinical trials. For example, Insilico Medicine used AI to identify drug candidates for idiopathic pulmonary fibrosis (IPF), a rare lung disease [31]. The algorithm analyzed gene expression data and identified several potential drug candidates that were later validated in preclinical models.

AI can also be used to optimize the drug development process, reducing the time and cost required to bring new drugs to market. For example, AI algorithms can be used to predict the safety and efficacy of potential drug candidates before they enter clinical trials. This can help pharmaceutical companies prioritize the most promising candidates and reduce the risk of costly clinical trial failures. In conclusion, the use of AI in drug discovery has the potential to significantly improve the drug development process and bring new treatments to patients faster.

AI in Clinical Trial Optimization

AI is increasingly being used to optimize clinical trials, improving the efficiency and effectiveness of the drug development process [32]. By analyzing patient data and predicting outcomes, AI algorithms can help pharmaceutical companies identify the most promising drug candidates and design clinical trials that are more likely to succeed [33].

One example of AI in clinical trial optimization is the use of machine learning algorithms to predict patient response to treatment [34]. These algorithms can analyze a range of data, including patient demographics, medical history, and genetic information, to identify which patients are most likely to benefit from a particular treatment. This can help pharmaceutical companies design more targeted clinical trials and increase the likelihood of success.

Another example is the use of AI to optimize the design of clinical trials [35]. AI algorithms can analyze data from previous trials to identify which designs are most effective in specific patient populations. This can help pharmaceutical companies design trials that are more likely to succeed, reducing the risk of costly failures.

A third example is the use of AI to monitor and analyze patient data during clinical trials. By analyzing data in real- time, AI algorithms can identify potential safety issues and adverse events more quickly than traditional monitoring methods [36]. This can help pharmaceutical companies address safety issues more quickly and reduce the risk of harm to patients. In conclusion, AI is playing an increasingly important role in the optimization of clinical trials, helping pharmaceutical companies design more targeted and effective trials and reducing the risk of costly failures. As AI continues to advance, it is likely to play an even greater role in the drug development process, ultimately leading to the development of more effective and safe treatments for patients.

AI in Biomarker Discovery

AI has become a valuable tool in biomarker discovery, facilitating the identification of novel biomarkers that can be used to diagnose, monitor, and treat a wide range of diseases [37]. By analyzing large amounts of data, including genomic, proteomic, and metabolomic data, AI algorithms can help researchers identify correlations between specific biomarkers and disease states [38].

One example of AI in biomarker discovery is the use of machine learning algorithms to analyze genomic data. By analyzing large datasets of genomic data, these algorithms can identify genetic mutations and variations that are associated with specific diseases or disease states [39]. This can help researchers identify potential biomarkers that can be used to diagnose and monitor disease progression.

Another example is the use of AI to analyze proteomic and metabolomic data [40]. By analyzing large datasets of proteomic and metabolomic data, AI algorithms can identify correlations between specific proteins or metabolites and disease states. This can help researchers identify potential biomarkers that can be used to diagnose and monitor disease progression.

Another example is the use of AI to identify biomarkers for cancer [41]. Researchers at the Dana-Farber Cancer Institute have used machine learning algorithms to identify a biomarker called “survivin,” which is highly expressed in several types of cancer [42]. This discovery could help improve the diagnosis and treatment of cancer, allowing for earlier detection and more targeted therapies.

Overall, AI has emerged as a powerful tool in biomarker discovery, helping researchers identify novel biomarkers that can be used to improve the diagnosis, monitoring, and treatment of a wide range of diseases [43]. As AI continues to advance, it is likely to play an even greater role in the discovery of new biomarkers, ultimately leading to improved patient outcomes.

Challenges of AI in Drug And Biomarker Discovery

One major challenge facing AI in drug and biomarker discovery is the need for large amounts of high-quality data [44]. AI algorithms rely on large datasets to identify patterns and correlations, and the quality of the data is critical to the accuracy of the results [45]. However, obtaining and curating large, high-quality datasets can be time-consuming and expensive, particularly in fields such as genomics and proteomics.

Another challenge is the interpretability of AI results [46]. While AI algorithms can identify patterns and correlations in data, it can be difficult to understand why a particular result was generated. This can make it challenging to translate AI findings into actionable insights for drug and biomarker discovery.

One other challenge is the lack of standardization in data collection and analysis [47]. Different labs and research groups may use different methods for collecting and analyzing data, which can make it difficult to compare results across studies. Standardization of data collection and analysis would improve the accuracy and reproducibility of AI findings in drug and biomarker discovery [48].

Future Directions

In terms of future directions, one key area of focus is the development of AI algorithms that can learn from smaller datasets [49]. This would be particularly valuable in fields such as rare diseases, where large datasets may not be available. Additionally, there is a need for more research into the interpretability of AI results, including the development of methods for explaining and visualizing AI-generated insights [50]. Another direction is the integration of multiple types of data, such as genomic, proteomic, and metabolomic data. This would allow for a more comprehensive understanding of disease states and the identification of more robust biomarkers for diagnosis, monitoring, and treatment.

Conclusion

Overall, while there are challenges to the use of AI in drug and biomarker discovery, there is great potential for AI to revolutionize these fields. By addressing these challenges and continuing to innovate in AI research, researchers can improve the accuracy, efficiency, and effectiveness of drug and biomarker discovery, ultimately leading to improved patient outcomes.

References

  1. Kersting K (2018) Machine learning and artificial intelligence: two fellow travelers on the quest for intelligent behavior in machines. Frontiers Media SA 6.
  2. Puaschunder JM (2019) Artificial intelligence in the healthcare sector. Scientia Moralitas-International Journal of Multidisciplinary Research 4(2): 1-14.
  3. Ahmed Z, Mohamed K, Zeeshan S, Dong X (2020) Artificial intelligence with multi-functional machine learning platform development for better healthcare and precision medicine. Database 2020.
  4. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, et al. (2019) Applications of machine learning in drug discovery and development. Nature reviews Drug discovery 18: 463-477.
  5. Gupta R, Devesh S, Mehar S, Swati T, Rashmi KA, et al. (2021) Artificial intelligence to deep learning: machine intelligence approach for drug discovery. Molecular diversity 25: 1315-1360.
  6. Vijayan R, Jan K, Jason BC, Vasanthanathan P (2022) Enhancing preclinical drug discovery with artificial intelligence. Drug discovery today 27(4): 967-984.
  7. Schork NJ (2019) Artificial intelligence and personalized medicine. Precision medicine in Cancer therapy 178: 265-283.
  8. Dubey A (2020) Showcasing the impact of machine learning in healthcare. Bioinformatics & Proteomics Open Access Journal 4(1): 1-4.
  9. Zhou Y, Wang F, Tang J, Nussinov R, Cheng F (202) Artificial intelligence in COVID-19 drug repurposing. The Lancet Digital Health 2(12): 667-676.
  10. Woolf PJ, Y Wang (2000) A fuzzy logic approach to analyzing gene expression data. Physiological Genomics 3(1): 9-15.
  11. Clarke R, Ressom HW, Wang A, Xuan J, Liu MC, et al. (2008) The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nature reviews cancer 8(1): 37-49.
  12. Mak KK, MR Pichika (2019) Artificial intelligence in drug development: present status and future prospects. Drug discovery today 24(3): 773-780.
  13. Aronson JK, RE Ferner (2017) Biomarkers-a general review. Current protocols in pharmacology 76(1): 1-9.
  14. Goswami A, C Kuppan, M Chavali (2017) Nanomedicine: Where we stand and where can we go?.
  15. Wang R, Jiao Z, Yang L, Choi JW, Xiong Z, et al. (2022) Artificial intelligence for prediction of COVID-19 progression using CT imaging and clinical data. European radiology 32: 205-212.
  16. Johnson M, Albizri A, Simsek S (2022) Artificial intelligence in healthcare operations to enhance treatment outcomes: a framework to predict lung cancer prognosis. Annals of Operations Research 308 1-31.
  17. Gambardella A (1995) Science and innovation: The US pharmaceutical industry during the 1980s. Cambridge University Press.
  18. You Y, Lai X, Pan Y, Zheng H, Vera J, et al. (2022) Artificial intelligence in cancer target identification and drug discovery. Signal Transduction and Targeted Therapy 7(156).
  19. Oliveira AL (2019) Biotechnology, big data and artificial intelligence. Biotechnology journal 14(8): 1800613.
  20. Porta Pardo E, Garcia Alonso L, Hrabe T, Dopazo J, Godzik A (2015)A pan-cancer catalogue of cancer driver protein interaction interfaces. PLoS computational biology 11(10): e1004518.
  21. Cockburn IM, Henderson R, Stern S (2018) The impact of artificial intelligence on innovation: An exploratory analysis, in The economics of artificial intelligence: An agenda University of Chicago Press pp: 115-146.
  22. Li J, Wu J, Zhao Z, Zhang Q, Shao J, et al. (2021) Artificial intelligence-assisted decision making for prognosis and drug efficacy prediction in lung cancer patients: A narrative review. Journal of Thoracic Disease 13(12): 7021-7033.
  23. Mohsen F, Hazrat Ali, Nady El Hajj, Shah Z (2022) Artificial intelligence-based methods for fusion of electronic health records and imaging data. Scientific Reports 12(17981).
  24. Adir O, Poley M, Chen G, Froim S, Krinsky N, et al. (2020) Integrating artificial intelligence and nanotechnology for precision cancer medicine. Advanced Materials 32(13): 1901989.
  25. Sharma A, Sharma N, Singh S, Dua K (2023) Review on theranostic and neuroprotective applications of nanotechnology in multiple sclerosis. Journal of Drug Delivery Science and Technology 81: 104220.
  26. Horn JR, PD Hansten, LN Chan (2007) Proposal for a new tool to evaluate drug interaction cases. Annals of Pharmacotherapy 41(4): 674-680.
  27. Johnson KB, Wei QW, Weeraratne D, Frisse ME, Misulis K, et al. (2021) Precision medicine, AI, and the future of personalized health care. Clinical and translational science 14(1): 86-93.
  28. Lo YC, Stefano ER, Torng W, Altman RB (2018) Machine learning in chemoinformatics and drug discovery. Drug discovery today 23(8): 1538-1546.
  29. Smalley E (2017) AI-powered drug discovery captures pharma interest. Nature Biotechnology 35(7): 604-606.
  30. Brasil S, Pascoal C, Francisco R, Vanessa Dos Reis F, Paula AV, et al. (2019) Artificial intelligence (AI) in rare diseases: is the future brighter? Genes 10(12): 978.
  31. Mak KK, Balijepalli M, Pichika MR (2022) Success stories of AI in drug discovery-where do things stand? Expert opinion on drug discovery 17(1): 79-92.
  32. Inan O, Tenaerts P, Prindiville SA, Reynolds HR, Dizon DS, et al. (2020) Digitizing clinical trials. NPJ digital medicine 3(1): 101.
  33. Battina DS (2017) The Role of Machine Learning in Clinical Research: Transforming the Future of Evidence Generation. FUTURE 4(12).
  34. Liang G, Fan W, Luo H, Zhu X (2020) The emerging roles of artificial intelligence in cancer drug development and precision therapy. Biomedicine & Pharmacotherapy 128: 110255.
  35. Nikooienejad A, Fu H (2022) AI/ML in Medical Research and Drug Development, in Advanced Statistics in Regulatory Critical Clinical Initiatives. Chapman and Hall/CRC pp: 133-156.
  36. Ghazal TM, Mohammad KH, Muhammad TA, Haitham MA, Ahmad M, et al. (2021) IoT for smart cities: Machine learning approaches in smart healthcare—A review. Future Internet 13(8): 218.
  37. Dana J, Aïna V, Antonio S, Joachim L, Yujin H, et al. (2022) Conventional and artificial intelligence-based imaging for biomarker discovery in chronic liver disease. Hepatology international 16(3): 509-522.
  38. Zhavoronkov A, Polina M, Quentin V, Morten SK, Alexey M, et al. (2019) Artificial intelligence for aging and longevity research: Recent advances and perspectives. Ageing research reviews 49: 49-66.
  39. Wright CF, Tomas W Fitzgerald, Wendy D Jones, Clayton S, Jeremy F McRae, et al. (2015) Genetic diagnosis of developmental disorders in the DDD study: a scalable analysis of genome-wide research data. The Lancet 385(9975): 1305-1314.
  40. Grapov D, Johannes F, Kwanjeera W, Sakda K (2018) Rise of deep learning for genomic, proteomic, and metabolomic data integration in precision medicine. Omics: a journal of integrative biology 22(10): 630-636.
  41. Elemento O, Christina L, Johan L, Georgia T (2021) Artificial intelligence in cancer research, diagnosis and therapy. Nature Reviews Cancer 21(12): 747-752.
  42. Lin F (2021) Immunotherapeutic Peptide Vaccine Approaches to Glioma. Journal of Cancer Research Reviews & Reports 151.
  43. Baxi V, Robin E, Michael M, Saurabh S (2022) Digital pathology and artificial intelligence in translational medicine and clinical practice. Modern Pathology 35(1): 23-32.
  44. Lekadir K, Leiner T, Alistair A Young, Steffen E Petersen (2020) Current and future role of artificial intelligence in cardiac imaging. Frontiers Media SA 7: 137.
  45. Dlamini Z, Francies FZ, Rodney H, Rahaba M (2020) Artificial intelligence (AI) and big data in cancer and precision oncology. Computational and structural biotechnology journal 18: 2300-2311.
  46. Reyes M, Raphael M, Sérgio P, Silva CA, Fried Michael D, et al. On the interpretability of artificial intelligence in radiology: challenges and opportunities. Radiology: artificial intelligence 2(3): e190043.
  47. Golenkov V, Natalia G, Vladimir G, Viktor K (2020) Artificial intelligence standardization is a key challenge for the technologies of the future. Open Semantic Technologies for Intelligent System pp: 1-12.
  48. Matthews H, J Hanison, N Nirmalan (2016) Omics- informed drug and biomarker discovery: opportunities, challenges and future perspectives. Proteomes 4(3): 28.
  49. Esteva A, Alexandre R, Bharath R, Volodymyr K, DePristo M, et al. (2019) A guide to deep learning in healthcare. Nature medicine 25(1): 24-29.
  50. Adadi A, Berrada M (2020) Explainable AI for healthcare: from black box to interpretable models. Embedded Systems and Artificial Intelligence Morocco pp: 327-337.
More from this journal

Cite this article

BibTeX
APA
RIS
@article{sharma2023,
  title   = {AI Powered Identification of Drug Targets and Pathways for
Diagnosis and Treatment Planning: A Review},
  author  = {Sharma A},
  journal = {Nanomedicine & Nanotechnology Open Access},
  year    = {2023},
  volume  = {8},
  number  = {2},
  doi     = {10.23880/nnoa-16000232}
}
Sharma A (2023). AI Powered Identification of Drug Targets and Pathways for
Diagnosis and Treatment Planning: A Review. Nanomedicine & Nanotechnology Open Access, 8(2). https://doi.org/10.23880/nnoa-16000232
TY  - JOUR
TI  - AI Powered Identification of Drug Targets and Pathways for
Diagnosis and Treatment Planning: A Review
AU  - Sharma A
JO  - Nanomedicine & Nanotechnology Open Access
PY  - 2023
VL  - 8
IS  - 2
DO  - 10.23880/nnoa-16000232
ER  -